12:00 AM
May 01, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Altropane: Phase II data; Phase III

BLSI said that a blinded analysis of SPECT scans from the company's previously reported Phase II trial by nuclear medicine specialists showed that Altropane provided a 96.4 percent sensitivity in detecting PD...

Read the full 139 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >